Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Biogen

3 Stocks to Own as Alzheimer's Drugs Bring Relief

The number of people with dementia, including those with Alzheimer's disease, are projected to increase from 50+ million now to more than 150 million in 2050, according to Alzheimer's Disease International. Those sheer numbers will mean that investors in certain stocks, producing Alzheimer's drugs to combat the disease, are poised…

StockNews.com

Stock Index Futures Move Higher as Investors Await Fed Rate Decision, U.S. PPI Data

June S&P 500 futures (ESM23) are up +0.12%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.16% this morning as market participants braced for the Federal Reserve’s interest rate decision while also awaiting crucial U.S. PPI data.

Barchart

Stocks Rally on Expectations the Fed Will Pause Rate Hikes

What you need to know… The S&P 500 Index ($SPX ) (SPY ) Tuesday closed up +0.69%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.43%, and the Nasdaq 100 Index ($IU XX) (QQQ ) closed up +0.79%. Stock indexes on Tuesday finished moderately higher, with the...

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Stocks Climb on the Outlook for the Fed to Pause Rate Hikes

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is up +0.51%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.42%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.32%. U.S. stocks this morning are moderately higher, with the...

Barchart

Experimental Alzheimer's drug endorsed for full approval by FDA advisers

Leqembi could become the first treatment of its kind to receive traditional approval from the FDA.

Axios

A Colorado panel of medical and pharmacy experts will decide whose medicine to make affordable this summer

Starting this summer, Colorado's Prescription Drug Affordability Board will choose up to 18 high-cost drugs for review.

Fortune

Drug for rare form of Lou Gehrig’s disease OK'd by FDA

U.S. health regulators have approved a first-of-a-kind drug for a rare form of Lou Gehrig’s disease

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

The VA will pay for some to get new Alzheimer’s drug

The U.S. Veterans Health Administration will pay for some beneficiaries to get a new Alzheimer’s disease drug from Eisai Co. and Biogen Inc., positive news for a treatment that Eisai expects to bring in billions of dollar in sales in the next few years.

Tribune News Service

Commentary: We shouldn’t get caught up in the hype over new Alzheimer’s drug

This month, the Food and Drug Administration approved a new drug, lecanemab, for the treatment of Alzheimer’s disease. The drug, sold under the brand name Leqembi, was developed by Japanese pharmaceutical company Eisai and will be marketed commercially in partnership with American pharmaceutical company Biogen. Biogen, notably, is the maker…

Chicago Tribune

Commentary: Too soon to celebrate new Alzheimer’s drug

A treatment that improves Alzheimer’s disease would be a great advance, but Leqembi (lecanemab), which recently received accelerated approval from the FDA, is not that drug. Yes, lecanemab slows decline to an extent detectable on a test, but not to an extent that a relative or caretaker would notice. This…

Tribune News Service

What the FDA's accelerated approval of a new Alzheimer's drug could mean for those with the disease – 5 questions answered about lecanemab

The U.S. Food and Drug Administration approved the medication lecanemab, sold under the brand name Leqembi, on Jan. 6, 2023, through an “accelerated approval pathway” that fast-tracks promising clinical treatments for diseases in which there are no other currently effective options.

The Conversation

US Approves New Drug to Treat Alzheimer's Disease

The US Food and Drug Administration on Friday approved a highly anticipated new drug designed to slow cognitive decline in patients in mild and early stages of Alzheimer's disease. The FDA approval of the drug, Leqembi, also known as lecanemab, comes just days after the regulatory agency was harshly criticized…

Asharq Al-Awsat

Alzheimer’s drug that slows disease progression approved by FDA

U.S. health officials have approved a new Alzheimer’s drug that modestly slows the brain-robbing disease

The Independent UK

FDA grants fast-track approval to experimental Alzheimer's drug

The FDA approved lecanemab, which has shown to slow the progression of Alzheimer's disease.

Axios

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Alzheimer's drug that modestly slows disease OK'd by FDA

U.S. health officials have approved a new Alzheimer’s drug that modestly slows the brain-robbing disease

Axios

2023 could be a banner year for prescription drugs

There's a large pipeline of promising yet expensive drugs that could get approved.

Tribune News Service

FDA’s approval of Biogen Alzheimer’s drug slammed in report

U.S. health officials’ approval process for Biogen Inc.’s controversial Alzheimer’s drug was “rife with irregularities,” raising serious concerns about protocol lapses at the agency, congressional investigators said.

The Independent UK

Probe: Alzheimer's drug approval 'rife with irregularities'

The Food and Drug Administration's contentious approval of a questionable Alzheimer's drug is taking another hit

Get all your
news in one place.

100’s of premium titles.
One news app.

Tribune News Service

House report questions FDA’s approval of Alzheimer’s drug

WASHINGTON — A joint investigation released Thursday by House Democrats identified unusual collaboration between Food and Drug Administration officials and drugmaker Biogen, highlighting potential problems in the agency’s approval of the controversial Alzheimer’s drug Aduhelm.

Roll Call

House report questions FDA's approval of Alzheimer's drug - Roll Call

House Democrats releases a report highlighting potential problems in the FDA's approval of Alzheimer's drug Aduhelm.

The Conversation

Lecanemab: Experimental drug is a ray of hope for Alzheimer's disease

On Nov. 30, Eisai and Biogen announced the results of their latest phase 3 clinical trial in Alzheimer’s disease. The verdict: an 18-month treatment with lecanemab slows functional and cognitive loss by 27 per cent in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. The study…

The New Daily

Lots of breakthroughs, still no cure. Do new dementia drugs bring us any closer?

We often hear about dementia breakthroughs in the news – new genes being discovered, new blood tests being developed, new drugs being tested.

The Conversation

Lots of 'breakthroughs', still no cure. Do the new dementia drugs bring us any closer?

We often hear about “dementia breakthroughs” in the news – new genes being discovered, new blood tests being developed, new drugs being tested.

Tribune News Service

Lisa Jarvis: That blockbuster Alzheimer’s drug? It’s not a cure

Biogen Inc. and Eisai Co. caused a stir in September when they announced positive results in a late-stage trial for a closely watched Alzheimer’s drug, lecanemab. Doctors tempered their excitement, though, until they could scrutinize the full peer-reviewed data.

Al Jazeera

Data shows drug slowing Alzheimer’s but doubts over effect remain

Lecanemab modestly slows disease’s inevitable worsening, but it remains unclear how much of a difference it will make.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.